Holding unique IP, MGC Pharmaceuticals’ Innovation division puts the Company at the forefront of exploration and development into indications that will serve large global markets.
Having recently attained GMP Certification at our European facility, MGC Pharma has commenced the full-scale commercial production of grade medical cannabis medicines containing THC and CBD APIs at its European production and compounding facility and will soon start clinical studies in epilepsy, based in Slovenia, in addition to the ongoing advancement of supplement and nutraceutical products. This is one more step in our Seed to Pharma strategy to become a leading BioPharma company with formulated medicines to sell into the global market. MGC also hopes to offer patients in Australia with these products and generate revenue from API sales.
Innovation Division: Having recently attained GMP Certification at our European facility, we can soon commence clinical studies in epilepsy, based in Slovenia.
Alongside these trials, we will also continue to work on the development of nutraceuticals and supplement products.
We also hope to make progress in providing patients in the Australian market with these products, as well as generate revenue from API sales.
Lenis: MGC Pharmaceuticals Ltd has signed a 5-year, Supply and Distribution Agreement with European pharmaceutical distribution company, Lenis farmacevtika d.o.o. (Lenis).
Epilepsy Action Australia: MGC Pharmaceuticals Ltd has signed a collaboration agreement with Australia’s leading Epilepsy association on future joint clinical trials.
HL Pharma: MGC Pharmaceuticals Ltd Australian Supply and Distribution company.